Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study by 강신욱 & 한승혁
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18964  | https://doi.org/10.1038/s41598-020-75888-8
www.nature.com/scientificreports
Polypharmacy, hospitalization, 
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Polypharmacy is a growing and major public health issue, particularly in the geriatric population. 
This study aimed to examine the association between polypharmacy and the risk of hospitalization 
and mortality. We included 3,007,620 elderly individuals aged ≥ 65 years who had at least one 
routinely‑prescribed medication but had no prior hospitalization within a year. The primary exposures 
of interest were number of daily prescribed medications (1–2, 3–4, 5–6, 7–8, 9–10, and ≥ 11) and 
presence of polypharmacy (≥ 5 prescription drugs per day). The corresponding comparators were 
the lowest number of medications (1–2) and absence of polypharmacy. The study outcomes were 
hospitalization and all‑cause death. The median age of participants was 72 years and 39.5% were 
men. Approximately, 46.6% of participants experienced polypharmacy. Over a median follow‑up of 
5.0 years, 2,028,062 (67.4%) hospitalizations and 459,076 (15.3%) all‑cause deaths were observed. 
An incrementally higher number of daily prescribed medications was found to be associated with 
increasingly higher risk for hospitalization and mortality. These associations were consistent 
across subgroups of age, sex, residential area, and comorbidities. Furthermore, polypharmacy was 
associated with greater risk of hospitalization and death: adjusted HRs (95% CIs) were 1.18 (1.18–1.19) 
and 1.25 (1.24–1.25) in the overall and 1.16 (1.16–1.17) and 1.25 (1.24–1.25) in the matched cohorts, 
respectively. Hence, polypharmacy was associated with a higher risk of hospitalization and all‑cause 
death among elderly individuals.
Polypharmacy refers to the prescription of multiple medications to a single individual, and it can be defined 
either numerically or  qualitatively1–5. Some studies have described polypharmacy as the use of a higher number 
of drugs than clinically  indicated2. However, this definition is based on a clinical judgement that is difficult to 
operationalize in large  studies5. By contrast, the numeric definition can vary according to practice setting or 
research protocol, and it is often used in most epidemiologic studies due to its simplicity (e.g., ≥ 5 prescription 
medications)3–5. Although there is no universal definition of polypharmacy to date, it is considered a growing 
and major public health problem worldwide, particularly among the geriatric population in whom there is a 
high burden chronic  comorbidities1,2,5.
Some patients with multiple comorbidities require the simultaneous prescription of pharmaceutical products. 
However, a growing body of evidence suggests that drugs are oftentimes prescribed inappropriately. Moreover, 
polypharmacy may be associated with adverse outcomes particularly in the elderly  population1,5. In fact, several 
symptoms related to the central nervous system and gastrointestinal tract are caused by adverse drug events, 
and additional drugs are often prescribed to control these  symptoms5–7. Such multiple drug combinations may 
lead to drug-drug interactions and heighten the risk of adverse  effects5–7. Furthermore, the use of multiple drugs 
can increase pill burden and medical  costs3. Concurrently, the prescription of multiple medications may nega-
tively affect patient adherence and health-related quality of life (HRQOL)8. Older individuals are particularly 
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vulnerable to unexpected drug-related problems because of the multiple drug regimens, higher number of 
comorbid conditions, and age-associated physiological changes in pharmacokinetics and pharmacodynamics 
with respect to certain  drugs5,9.
There have been a number of studies that examined the relationship between polypharmacy and adverse 
events. The prevalence of polypharmacy has consistently increased, which is particularly evident among elderly 
 individuals9–12. Predictably, the number of prescribed medications increases concomitantly with age and num-
ber of  comorbidities13. To date, several epidemiologic studies reported possible detrimental associations of 
polypharmacy with  falls14, renal  failure15,  frailty16, poor physical  function17, and cognitive  impairment18,19. In 
addition, patients consuming multiple medications are more likely to experience poor  HRQOL20,21 and frequent 
 hospitalizations22–24. More importantly, in a recent meta-analysis that pooled data across 47 studies, polyphar-
macy, defined as ≥ 5 prescribed drugs, was associated with a 31% higher risk for  mortality25. However, not all 
studies have confirmed this  association26,27. Nevertheless, interpretation of these aforementioned studies are 
limited by potential residual confounders and confounding by indication (i.e., higher number of medications 
prescribed to those with ill health), medication ascertainment by self-report (i.e., which results in exposure 
misclassification), and examination of drug exposure within a short period (i.e., ~ 30 days) (i.e., which limits the 
examination of long-term exposure-outcome associations). Thus, to better inform the field, we sought to examine 
the association of polypharmacy with the risk of hospitalization and death in a large longitudinal cohort of elderly 
community-indwelling individuals from the Korean National Health Insurance Service (NHIS) database linked 
to the nationwide pharmacy claims data.
Results
Baseline characteristics of the study population. The flow chart of study cohort construction and 
the baseline characteristics of 3,007,620 participants who met the eligibility criteria of the study are shown in 
Supplementary Fig. S1 and Table 1, respectively. The median (inter-quartile range, IQR) age of the participants 
was 72 years (68–77 years), among whom 39.5% (95% confidence interval [CI], 39.4%-39.6%) were men, 86.3% 
(95% CI, 86.3%-86.3%) were urban residents, and 81.5% (95% CI, 81.5%-81.5%) had at least one comorbidity 
based on the Charlson comorbidity index (CCI). In the study population, the mean (standard deviation, SD) and 
median (IQR) numbers of daily prescribed medications were 4.9 (3.2) and 4.0 (2.0–7.0), respectively. Individu-
als who were prescribed with a greater number of medications were more likely to be older and have a higher 
prevalence of comorbidities. Overall, the distributions of sex and residential area were similar across the groups.
Relationship between the number of medications and risk of hospitalization or death. During 
a median follow-up period of 5.0 years, 2,028,062 (67.4%; 95% CI, 67.3%-67.5%) hospitalizations and 459,076 
(15.3%; 95% CI, 15.3%-15.3%) deaths from any cause were observed, with corresponding crude incidence rates 
of 228.5 (95% CI, 228.2–228.8) and 32.5 (95% CI, 32.4–32.5) per 1000 person-years, respectively. An incremen-
tally higher number of daily prescribed medications was associated with a stepwise increase in outcome event 
rates (Supplementary Fig. S2).
In the Cox regression models adjusted for socio-demographic data and comorbidities, there was a graded 
association between the number of daily prescribed medications and the risks of hospitalization and death (Fig. 1 
and Table 2). Considering a potential heterogeneous population, we conducted subgroup analyses stratified by 
age, sex, residential area, and comorbidity burden. We found that the graded relationships between the number 
of medications and adverse outcomes were consistent across these subgroups (Figs. 2 and 3 and Supplementary 
Table S1).
Polypharmacy and risk of hospitalization or death. We then sought to examine the association 
between polypharmacy and the risk of hospitalization and death. The overall prevalence rate of polypharmacy 
was 46.6% (95% CI 46.5–46.7%). In the overall cohort, individuals with polypharmacy were older and had a 
higher comorbidity burden compared to those without polypharmacy (Supplementary Table S2). In the multi-
variate Cox models adjusted for age, sex, residential area, and CCI score, polypharmacy was found to be associ-
ated with significantly a higher risk of hospitalization and mortality (adjusted HRs [95% CIs]: 1.18 (1.18–1.19) 
and 1.25 (1.24–1.25), respectively).
In the propensity score analyses, we identified 1,070,337 matched pairs of individuals with vs. without poly-
pharmacy whose baseline characteristics were well balanced (Supplementary Table S2). In the matched cohort, 
there were 1,463,971 (68.4%; 95% CI, 68.3–68.5%) hospitalizations and 332,782 (15.6%; 95% CI, 15.6–15.6%) 
mortality cases. Similar to the findings observed in the overall cohort, polypharmacy was associated with a signifi-
cantly higher risk of hospitalization and mortality. The corresponding HRs (95% CI) for each outcome were 1.16 
(1.16–1.17) and 1.25 (1.24–1.25), respectively (Supplementary Table S3). Moreover, the Kaplan–Meier analyses 
revealed that individuals with polypharmacy had a significantly higher rate of hospitalization and mortality 
than those without polypharmacy in both the overall and matched cohorts (Supplementary Figs. S3 and S4).
Discussion
In this large national longitudinal cohort study, we found a graded association between the number of medica-
tions and the risk of adverse clinical outcomes among individuals aged 65 years or older. This association was 
consistent across clinically relevant subgroups stratified according to age, sex, residential area, and comorbid-
ity burden. Furthermore, polypharmacy was associated with a significantly higher risk of hospitalization and 
mortality in both the overall and propensity-score matched cohorts. Thus, polypharmacy might have ill effects 
on the health and survival of elderly people.
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Table 1.  Baseline characteristics of 3,007,620 participants stratified by the number of daily prescribed 
medications. Data are presented as means ± standard deviation, number, or percentages. CCI Charlson 
comorbidity index.
Characteristic Overall
Number of routinely-prescribed medications (per day)
1 to 2 3 to 4 5 to 6 7 to 8 9 to 10  ≥ 11
Number of participants 3,007,620 764,673 841,498 618,087 388,520 211,000 183,842
Number of medications 4.9 ± 3.2 1.6 ± 0.5 3.5 ± 0.5 5.5 ± 0.5 7.4 ± 0.5 9.4 ± 0.5 12.9 ± 2.4
Age, years 73.4 ± 6.3 72.6 ± 6.2 73.1 ± 6.3 73.7 ± 6.3 74.0 ± 6.3 74.3 ± 6.2 74.3 ± 6.0
65–69 years, % 31.5 37.2 33.3 29.5 26.7 24.9 23.8
70–74 years, % 31.0 30.8 31.2 31.1 30.9 30.6 31.1
75–79 years, % 20.7 17.9 19.7 21.5 23.0 24.2 25.3
 ≥ 80 years, % 16.9 14.1 15.8 18.0 19.5 20.4 19.8
Gender, % men 39.5 38.5 40.1 39.8 39.2 39.3 40.6
Residential area, %
Large city 43.5 44.6 43.8 43.1 42.5 42.4 42.5
Small city 42.8 42.1 42.8 43.0 43.2 43.1 43.8
Rural area 13.7 13.2 13.4 13.9 14.3 14.4 13.7
CCI scores 2.0 ± 1.7 1.3 ± 1.4 1.7 ± 1.5 2.2 ± 1.7 2.6 ± 1.8 3.0 ± 2.0 3.6 ± 2.0
0, % 18.5 32.4 22.4 12.5 7.5 4.7 2.5
1, % 27.6 32.1 31.8 28.0 22.4 17.6 11.4
2, % 22.2 19.1 22.3 24.9 24.9 23.1 18.9
 ≥ 3, % 31.7 16.5 23.5 34.7 45.2 54.6 67.3
Comorbid conditions, %
Hypertension 79.5 65.0 79.1 84.1 88.6 91.1 93.2
Diabetes 36.9 19.9 29.8 42.2 51.5 58.5 67.1
Acute myocardial infarction 1.9 0.4 1.0 2.4 3.4 4.2 5.0
Heart failure 4.7 1.4 3.1 5.7 7.7 9.4 11.1
Cerebrovascular disease 13.9 5.0 10.1 16.5 21.1 24.9 30.6
Hemiplegia 1.0 0.3 0.6 1.2 1.6 2.0 2.5
Dementia 6.8 4.0 5.2 7.2 9.1 10.9 14.0
Peripheral vascular disease 20.4 13.3 20.1 22.4 24.3 23.0 29.5
Liver disease 5.9 5.2 5.6 6.1 6.4 6.8 7.7
Chronic pulmonary disease 26.3 23.2 24.1 26.4 29.0 31.6 36.3
Connective tissue disease 6.3 4.8 5.3 6.4 7.6 8.8 10.9
Peptic ulcer disease 34.7 31.0 31.9 35.2 38.0 41.0 46.5
Chronic kidney disease 1.3 0.5 0.8 1.3 2.0 2.8 4.2
Malignancy 6.7 6.9 6.2 6.5 6.7 7.1 8.0
BA
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Figure 1.  Associations between the number of daily prescribed medications with the risk of (A) hospitalization 
and (B) mortality. All models were adjusted for age, sex, residential area, and Charlson comorbidity index score.
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Table 2.  Associations between the number of daily prescribed medications and adverse outcomes. 
Adjustments in model (1): unadjusted; model (2): age, sex, residential area; and model (3): all covariates in 




(per 1000 PYs) Model 1 Model 2 Model 3
Incidence 95% CI HR 95% CI p HR 95% CI p HR 95% CI p
Hospitalization
1 to 2 191.6 (191.1–192.2) 1.00 1.00 1.00
3 to 4 208.4 (207.8–208.9) 1.09 (1.08–1.09)  < 0.001 1.07 (1.07–1.08)  < 0.001 1.05 (1.04–1.05)  < 0.001
5 to 6 236.4 (235.7–237.1) 1.23 (1.22–1.24)  < 0.001 1.20 (1.20–1.21)  < 0.001 1.13 (1.12–1.13)  < 0.001
7 to 8 267.3 (266.3–268.3) 1.39 (1.38–1.39)  < 0.001 1.34 (1.34–1.35)  < 0.001 1.22 (1.22–1.23)  < 0.001
8 to 10 298.1 (296.6–299.6) 1.54 (1.54–1.55)  < 0.001 1.49 (1.48–1.50)  < 0.001 1.31 (1.31–1.32)  < 0.001
 ≥ 11 344.1 (342.3–345.8) 1.78 (1.77–1.79)  < 0.001 1.71 (1.70–1.72)  < 0.001 1.45 (1.44–1.46)  < 0.001
Death
1 to 2 23.3 (23.2–23.5) 1.00 1.00 1.00
3 to 4 27.7 (27.5–27.8) 1.17 (1.16–1.18)  < 0.001 1.12 (1.11–1.13)  < 0.001 1.08 (1.07–1.09)  < 0.001
5 to 6 34.4 (34.2–34.6) 1.42 (1.41–1.43)  < 0.001 1.29 (1.28–1.31)  < 0.001 1.20 (1.19–1.21)  < 0.001
7 to 8 40.8 (40.5–41.1) 1.65 (1.63–1.67)  < 0.001 1.47 (1.46–1.49)  < 0.001 1.31 (1.30–1.33)  < 0.001
8 to 10 47.0 (46.5–47.4) 1.86 (1.84–1.88)  < 0.001 1.63 (1.61–1.65)  < 0.001 1.41 (1.39–1.42)  < 0.001
 ≥ 11 54.1 (53.6–54.6) 2.11 (2.09–2.14)  < 0.001 1.89 (1.87–1.92)  < 0.001 1.54 (1.52–1.56)  < 0.001







































































Age 65~69 years (N=946,658)
Age 70~74 years (N=931,790)
Age 75~79 years (N=622,385)
Age ≥80 years (N=506,787)
Figure 2.  Subgroup analyses of the association between the number of daily prescribed medications and the 
risk of hospitalization. Subgroup analyses were performed and stratified by (A) age (65–69, 70–74, 75–80, 
and ≥ 80 years), (B) sex (men and women), (C) residential area (large city, small city, and rural area), and (D) 
comorbidity burden (CCI scores: 0, 1, 2, and ≥ 3). All models were adjusted for age, sex, residential area, and 
CCI score. CCI Charlson comorbidity index.
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With increasing longevity, individuals are more likely to present with a higher number of health problems 
as well as treatment with multiple drugs. Accordingly, there has been a growing concern that polypharmacy 
may result in adverse drug-drug interactions, particularly in the elderly  population5–7. For example, a previous 
study using the Swedish Drug Register showed a strong relationship between the number of dispensed drugs 
and possible drug-drug  interactions28,29. Although drugs are provided to improve patients’ health status, the 
risk of prescribing multiple concomitant drugs may outweigh individual benefits due to potential ensuing side 
 effects6,30. To date, several studies have shown that the use of multiple medications is associated with a broad 
range of adverse clinical events including falls, fractures, kidney impairment, frailty, poor HRQOL, cognitive 
dysfunction, and  hospitalization14–24. However, in these studies, it is difficult to determine whether poor health 
status or the prescription of multiple drugs occurred first. For example, a high number of prescribed drugs may 
be a proxy for illness, without direct causal link with adverse outcomes, making it difficult to estimate the effects 
polypharmacy on health status. Despite rigorous adjustment for comorbidities, confounding by illness may persist 
in observational studies examining the association between polypharmacy and health outcomes.
Although polypharmacy has been associated with the abovementioned complications, studies examining the 
relationship between polypharmacy and mortality risk have been mixed. A meta-analysis by Leelakanok et al.25 
found a dose–response relationship between the number of prescribed medications and mortality. However, this 
analysis examined a highly heterogeneous population and could not rule out the possibility of residual confound-
ing affecting the pooled estimates. In contrast, two consecutive studies by Schöttker et al.31,32 sought to mitigate 
the influence of confounding by indication using two approaches. In the analyses that performed multivariate 
adjustment for chronic conditions, polypharmacy was found to be associated with a two-fold higher risk of 
non-cancer related mortality in older German  adults31. However, in analyses that examined cohorts who were 
matched upon baseline characteristics using propensity scores, the associations were attenuated to the  null31. 
Nevertheless, in another observational study conducted in Taiwan in which polypharmacy and comorbidities 
were examined as time-varying exposures, polypharmacy was not associated with a higher death risk among 
adults aged 65 years and  older23.
In the present study, we sought to address the issue of confounding by indication using three approaches, 








































































Age 65~69 years (N=946,658)
Age 70~74 years (N=931,790)
Age 75~79 years (N=622,385)
Age ≥80 years (N=506,787)
Figure 3.  Subgroup analyses of the association between the number of daily prescribed medications and the 
risk of all-cause mortality. Subgroup analyses were performed and stratified by (A) age (65–69, 70–74, 75–80, 
and ≥ 80 years), (B) sex (men and women), (C) residential area (large city, small city, and rural area), and (D) 
comorbidity burden (CCI scores: 0, 1, 2, and ≥ 3). All models were adjusted for age, sex, residential area, and 
CCI score. CCI Charlson comorbidity index.
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3) propensity-score matching analyses. In the conventional Cox models adjusted for disease burden, a higher 
number of daily prescribed medications was associated with a greater risk of hospitalization and death. Moreo-
ver, graded associations were largely similar across all subgroups stratified by CCI score. Furthermore, in the 
propensity-score matched analyses, individuals with polypharmacy had a 1.2- and 1.3-fold higher risk of hos-
pitalization and mortality. In summary, all three approaches demonstrated a consistent association between 
polypharmacy and a higher risk of hospitalization and death. To the best of our knowledge, to date, this is the 
largest study that examined over three million elderly adults in Korea, thereby providing a strong statistical power. 
While the underlying mechanisms responsible for polypharmacy-related adverse outcomes should be further 
investigated, our findings highlight the need to identify strategies that can reduce polypharmacy in clinical prac-
tice and motivate more judicious prescription of multiple medications, particularly in the geriatric population.
In relation to this, there have been efforts to reduce polypharmacy and inappropriate prescribing prac-
tices through educational interventions or alert  systems33–36. One of these studies included the D-PRESCRIBE 
(Developing Pharmacist-Led Research to Educate and Sensitize Community Residents to the Inappropriate 
Prescriptions Burden in the Elderly), which is a recent randomized controlled trial involving older adults in 
 Quebec36. This study showed that a pharmacist-led educational intervention resulted in greater discontinua-
tion of inappropriately prescribed medications after six  months36. However, at present, most studies have only 
examined the short-term effects of interventions on prescribing patterns. Hence, further long-term studies are 
required to investigate whether strategies for reducing polypharmacy can significantly improve “hard” clinical 
endpoints such as hospitalization and mortality.
Several limitations of our study bear mention. First, given that the Korean NHIS database only captures 
information on prescribed medication, data on the use of over-the-counter, complementary, and alternative 
drugs were not obtained. In addition, drugs prescribed for short-term intervals were not considered and detailed 
information on the duration of drug use and the number of medications before study entry was not collected. 
Furthermore, there was no information on long-acting drugs prescribed once a week or month and other types 
of medications such as injections, inhalers, eye drops, and topical agents. These drugs might also result in 
adverse reactions. Hence, the current study might have underestimated the actual prevalence of polypharmacy 
in this population. Moreover, we determined the number of medications consumed based on prescription data. 
However, they do not convey information on adherence to the prescribed medications nor the actual number 
of pills taken by the patients. Second, our definition of polypharmacy was based on a cutoff of ≥ 5 prescriptions, 
which has been used in prior  studies12,13,19,25,28,31–33. However, this threshold may not be applicable to all patients. 
Therefore, future studies are needed to ascertain inappropriate prescriptions using more sophisticated approaches 
such as the  Beers37 or the STOPP (Screening Tool of Older Peoples Prescriptions)38 criteria. In a recent study by 
Nam et al.39, the prevalence of potentially inappropriate prescribing (PIP) was remarkably high among Korean 
elderly individuals based on the 2012 Beers criteria. Currently, we are collecting relevant data to analyze the 
association between PIP and clinical consequences in corollary studies. Third, although a series of sensitivity 
analyses were conducted to try to account for potential confounding by indication and reverse causation, residual 
confounding could not be excluded. In fact, the number of individuals without any CCI comorbidity had at least 
one prescribed medication. Thus, they are likely to have other comorbid conditions that might not be captured 
by CCI score, thereby causing confounding effects. Finally, this study was conducted on non-institutionalized 
elderly individuals; thus, our findings might only be generalizable to community-dwelling elderly individuals 
not to those living in nursing homes or younger populations.
In conclusion, polypharmacy was associated with a higher risk of hospitalization and all-cause mortality in 
a large national cohort of Korean elderly individuals. These findings underscore the risk of prescribing multiple 
pharmaceutical products and highlight the urgent need for judicious and appropriate prescription practices and 
identification of strategies that avoid polypharmacy in the geriatric population.
Methods
Source population. We obtained data from the Korean NHIS database, which is linked to nationwide 
pharmacy claims data. Since NHIS, which is a single-payer national health system, covers compulsory health 
insurance for all citizens in Korea, all medical records of covered inpatient and outpatient visits are centralized in 
the NHIS database. These include diagnostic codes, procedures, prescriptions, medical costs, and personal infor-
mation (e.g., age, sex, residential area, and death records)40,41. The pharmacy claims database provides details on 
all prescription medications for each individual, which include drug names (generic and brand names), start and 
end dates of prescription, number of days for drug supply, and prescribed doses.
The source population comprised 6,100,982 elderly individuals aged ≥ 65 years who were captured in the 
2012 NHIS database. We first excluded 1,876,821 individuals who were hospitalized or who died during the 
exposure period from January 1, 2012, to December 31, 2012. To determine the association between the number 
of routinely prescribed medications and adverse outcomes, we further excluded 1,216,541 individuals who were 
not prescribed any medications or who received a prescription for ≤ 270 days in 2012. Therefore, the final study 
population comprised 3,007,620 individuals (Supplementary Fig. S1). The study was carried out in accordance 
with the Declaration of Helsinki. The Institutional Review Board of NHIS Ilsan Hospital approved this study, 
and the need for informed consent was waived as only deidentified data were examined.
Data collection and measurements. Baseline data on sociodemographic information such as age, sex, 
and residential area were collected in the year of study entry. Comorbidities (e.g., hypertension, diabetes, acute 
myocardial infarction, congestive heart failure, cerebrovascular disease, hemiplegia, dementia, peripheral vas-
cular disease, liver disease, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, chronic 
kidney disease, and malignancy) were assessed using the International Statistical Classification of Disease and 
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Related Health Problems, Tenth Revision, coding algorithms. The presence of comorbidities was confirmed by 
the presence of at least one diagnostic code identified up to one year prior to the exposure period. Moreover, the 
CCI score was calculated as a proxy of disease burden and illness  severity42.
Data on outpatient prescription medications were identified from the pharmacy claims database and were 
extracted using specific drug-class codes or names. To determine the risk associated with longer periods of drug 
exposure, we only selected “routinely-prescribed” medications, which was defined as medications prescribed 
for ≥ 270 days from January 1, 2012, to December 31, 2012. The number of drugs was counted according to the 
fifth level of the Anatomical Therapeutic Chemical (ATC) Classification  System43. Drugs which had the same 
fifth level of ATC code were considered as one drug. In the case of combined products containing two or more 
active components, the number of drugs was calculated as the sum of the number of each active ingredient. 
Only drugs of oral formulations were included, and other types of drugs such as injections, inhalers, eye drops, 
and topical agents were excluded. Moreover, long-acting drugs prescribed once a week or month were excluded.
Exposure and outcome ascertainment. The co-primary exposures of interest were the (1) number of 
daily prescribed medications and (2) presence vs. absence of polypharmacy. The number of daily prescribed 
drugs was categorized into six groups (1–2, 3–4, 5–6, 7–8, 9–10, and ≥ 11), and polypharmacy was defined as the 
use of ≥ 5 prescription drugs per day.
The study outcomes of interest were hospitalization and all-cause mortality, which were assessed via a time-
to-first-event analysis. Follow-up started on January 1, 2013 (index date) and ended during the occurrence of 
any event or until December 31, 2017 (study end date), which ever came first.
Statistical analysis. Data from the descriptive analyses were summarized using means (SD), medians 
(IQR), or proportions according to data type. To determine potential dose–response relationships, we first 
examined the associations between the number of medications and study outcomes using the Cox propor-
tional hazard regression models with three incremental levels of adjustment. These levels were as follows: (1) 
Model 1: unadjusted; (2) Model 2: adjusted for age, sex, and residential area; and (3) Model 3 (fully-adjusted 
model): adjusted for all covariates in model 2 plus the CCI score. To test the robustness of our findings, we also 
performed subgroup analyses across the following of clinically relevant subgroups: age (65–69, 70–74, 75–80, 
and ≥ 80 years), sex (men and women), residential area (large city, small city, and rural area), and comorbidity 
burden (CCI scores: 0, 1, 2, and ≥ 3).
Next, to assess the associations between polypharmacy and the risk of hospitalization and death, we converted 
the number of medications into a binary exposure of polypharmacy (≥ 5 vs. 1–4 medications prescribed daily). 
This was then examined using the Cox models adjusted for age, sex, residential area, and CCI score in the overall 
and propensity-score matched cohorts. In establishing the propensity-score matched cohort, we matched indi-
viduals with and without polypharmacy (1:1 ratio) based on age, sex, residential area, and CCI scores. Further, 
time to the first occurrence of any hospitalization or death was also evaluated and compared between the two 
groups based on the number of medications or presence of polypharmacy using the Kaplan–Meier method and 
the log-rank test. There were no missing data in our study. All analyses were conducted using Stata version 15.1 
(Stata Corporation, College Station, TX).
Ethical approval. The current study was approved by the Institutional Review Board of the National Health 
Insurance Service Ilsan Hospital (NHIMC 2019-06-014).
Informed consent. The Institutional Review Board of the National Health Insurance Service Ilsan Hospital 
waived the need for informed consent as only deidentified data were examined.
Data availability
All relevant data are included in the manuscript and its supporting information files. Technical appendix and 
statistical code are available from Dr. Chang (email: kidneyjang@gmail.com).
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